Altus Formulation is a drug formulation and development company leveraging our patented drug delivery technologies to provide innovative, cost-effective Safer to Use (TM) formulations for our clients and their patients. IINTELLITAB (TM) technology is an innovative new platform addressing the epidemic of prescription drug abuse. INTELLITAB Technology uses only well proven ingredients and simple manufacturing techniques to generate Safer to Use tablets’ meeting your clinical and regulatory needs. FLEXITAB (TM) technology safely eliminates the need for multiple tablet strengths enabling for the first time scored extended release tablets that may be broken with no change in performance; FLEXITAB tablets don’t dose dump. With FLEXITAB patients may be titrated simply from just one tablet in a cost-effective and safe manner. PNDS (TM) offers a solution to insoluble drug delivery for small and large molecules alike; PNDS Parenteral: Altus PNDS micelles have achieved increases in water solubility of over half a million fold. Their high tolerability, robustness and ease of use facilitates rapid cost effective development of low viscosity low volume formulations for parenteral delivery at high concentration. PNDS Oral: These pH sensitive nanosystems target delivery to the upper GI to maximize absorption while their low crystallinity retains drug in amorphous form even at loading levels of 80% drug. Altus offers full service development services to our clients and partners including method development, formulation design and testing, process development and clinical and registration batch manufacture. We can also manage your regulatory submissions and first in man studies.
Looking for a particular Altus Formulation Inc. employee's phone or email?
The Altus Formulation Inc. annual revenue was $4 million in 2026.
1 people are employed at Altus Formulation Inc..
Altus Formulation Inc. is based in Laval, Quebec.
The NAICS codes for Altus Formulation Inc. are [325, 32, 3254, 32541].
The SIC codes for Altus Formulation Inc. are [283, 28].